Literature DB >> 21484293

Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux.

Carlos G Santos-Gallego1, Chiara Giannarelli, Juan José Badimón.   

Abstract

Reduction of low-density lipoprotein cholesterol by statin therapy has only modestly decreased coronary heart disease (CHD)-associated mortality in developed countries, which has prompted the search for alternative therapeutic strategies for CHD. Epidemiologic and interventional studies have clearly established an inverse association between plasma levels of high-density lipoprotein (HDL) cholesterol and incidence of atherosclerosis. The atheroprotective benefits of HDL are not only dependent on HDL concentrations (quantity), but also on HDL function (quality). Therefore, several techniques have been recently developed to assess the different properties of HDL. Because reverse cholesterol transport (RCT) is considered a key player in the beneficial action of HDL, this review focuses on the different methods used to evaluate cholesterol efflux. Measuring the in vivo function of HDL could be of significant importance for both the clinical evaluation of an individual patient and to evaluate the effectiveness of different RCT-enhancing therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21484293     DOI: 10.1007/s11883-011-0177-0

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  48 in total

Review 1.  In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection.

Authors:  Joan Carles Escolà-Gil; Noemí Rotllan; Josep Julve; Francisco Blanco-Vaca
Journal:  Atherosclerosis       Date:  2009-03-21       Impact factor: 5.162

2.  Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men.

Authors:  U Goldbourt; S Yaari; J H Medalie
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-01       Impact factor: 8.311

3.  Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans.

Authors:  M Eriksson; L A Carlson; T A Miettinen; B Angelin
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

4.  Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels.

Authors:  K F Kozarsky; M H Donahee; A Rigotti; S N Iqbal; E R Edelman; M Krieger
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

5.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

6.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

7.  Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration.

Authors:  C D Jolley; L A Woollett; S D Turley; J M Dietschy
Journal:  J Lipid Res       Date:  1998-11       Impact factor: 5.922

8.  Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages.

Authors:  Ephraim Sehayek; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-04-17       Impact factor: 8.311

9.  Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Authors:  Michiel L Bots; Frank L Visseren; Gregory W Evans; Ward A Riley; James H Revkin; Charles H Tegeler; Charles L Shear; William T Duggan; Ralph M Vicari; Diederick E Grobbee; John J Kastelein
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

10.  The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.

Authors:  Urbain Tchoua; Wilissa D'Souza; Nigora Mukhamedova; Denise Blum; Eric Niesor; Jacques Mizrahi; Cyrille Maugeais; Dmitri Sviridov
Journal:  Cardiovasc Res       Date:  2007-12-04       Impact factor: 10.787

View more
  18 in total

1.  Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.

Authors:  Yunqin Chen; Jibin Dong; Xiaojin Zhang; Xueying Chen; Li Wang; Haozhu Chen; Junbo Ge; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2019-04-14       Impact factor: 5.162

Review 2.  Role of HDL in those with diabetes.

Authors:  Carlos G Santos-Gallego; Robert S Rosenson
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

3.  Cholesterol efflux capacity does not associate with coronary calcium, plaque vulnerability, and telomere length in healthy octogenarians.

Authors:  Francesca Zimetti; Wladimir M Freitas; Alessandra M Campos; Mauricio Daher; Maria Pia Adorni; Franco Bernini; Andrei C Sposito; Ilaria Zanotti
Journal:  J Lipid Res       Date:  2018-02-07       Impact factor: 5.922

Review 4.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

Review 5.  An eicosanoid-centric view of atherothrombotic risk factors.

Authors:  Scott Gleim; Jeremiah Stitham; Wai Ho Tang; Kathleen A Martin; John Hwa
Journal:  Cell Mol Life Sci       Date:  2012-04-11       Impact factor: 9.261

6.  Development of a tree shrew metabolic syndrome model and use of umbilical cord mesenchymal stem cell transplantation for treatment.

Authors:  Xing-Hua Pan; Lu Zhu; Xiang Yao; Ju-Fen Liu; Zi-An Li; Jian-Yong Yang; Rong-Qing Pang; Guang-Ping Ruan
Journal:  Cytotechnology       Date:  2016-03-21       Impact factor: 2.058

7.  Postmenopausal Women Have Higher HDL and Decreased Incidence of Low HDL than Premenopausal Women with Metabolic Syndrome.

Authors:  Maria Luz Fernandez; Ana Gabriela Murillo
Journal:  Healthcare (Basel)       Date:  2016-03-16

8.  Lipidomic and Antioxidant Response to Grape Seed, Corn and Coconut Oils in Healthy Wistar Rats.

Authors:  Abraham Wall-Medrano; Laura A de la Rosa; Alma A Vázquez-Flores; Gilberto Mercado-Mercado; Rogelio González-Arellanes; José A López-Díaz; Aarón F González-Córdova; Gustavo A González-Aguilar; Belinda Vallejo-Cordoba; Francisco J Molina-Corral
Journal:  Nutrients       Date:  2017-01-20       Impact factor: 5.717

Review 9.  High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.

Authors:  Emmanuel Androulakis; Effimia Zacharia; Nikolaos Papageorgiou; Eirini Lioudaki; Dimitris Bertsias; Marietta Charakida; Gerasimos Siasos; Dimitris Tousoulis
Journal:  Curr Cardiol Rev       Date:  2017

10.  Metabolic Syndrome Modulates Association between Endothelial Lipase and Lipid/Lipoprotein Plasma Levels in Acute Heart Failure Patients.

Authors:  Ines Potočnjak; Matias Trbušić; Sanda Dokoza Terešak; Bojana Radulović; Gudrun Pregartner; Andrea Berghold; Beate Tiran; Gunther Marsche; Vesna Degoricija; Saša Frank
Journal:  Sci Rep       Date:  2017-04-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.